Search

Search Constraints

You searched for: Author/Creator Provenzano, Elena

Search Results

2. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

3. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Issue 10191 (29th June 2019)

4. A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Issue 1 (8th August 2014)

5. Achieving margin clearance following oncoplastic breast surgery in comparison with simple wide local excision: a three‐dimensional specimen assessment. Issue 11 (17th August 2020)

6. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Issue 6 (June 2017)

9. Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). Issue 1 (7th January 2022)

10. Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. Issue 1 (22nd March 2013)